Full Press Release Details
Medical Showcases a Working Prototype of its Self-Cleaning Shunt
MA - January 17, 2019 - Microbot Medical Inc. (Nasdaq CM: MBOT) demonstrated an activated Self-Cleaning Shunt (SCSTM)
during recent one-on-one investor and analyst meetings in San Francisco, which took place during the same week as the JP Morgan
Healthcare conference. The Company's SCSTM was activated from a working prototype of its customized headset that
is intended to be used periodically by either the patient or the healthcare provider for the operation of the SCSTM.
our recent successful lab and pre-clinical testing of the SCSTM, coupled with the progress we made with the development
of our SCSTM device, we are pleased to see the enormous interest and positive feedback from the professional community
as we start exposing them to the device", commented Harel Gadot, President, Chief Executive Officer and Chairman of Microbot.
small-group demonstrations followed a live demonstration of the headset at the International Society for Hydrocephalus and Cerebrospinal
Fluid Disorders (ISHCFD) annual meeting held in Bologna, Italy in October 2018. The ISHCFD was also the first time that, in front
of leading global neurologists, the Company's pre-clinical study results were presented by Professor Pat McAllister, Department
of Neurosurgery, Washington University School of Medicine, St. Louis. Dr. McAllister's presentation was titled "Biocompatibility
of the Novel Microbot Medical SCSTM Shunt Catheter" and was part of the Company's participation at
the annual meeting. It highlighted:
| In-vitro study performed at Wayne State University, which supports the SCS TM 's potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus. | ||
| In-vivo animal study performed at Washington University School of Medicine in St. Louis, which supports the safety profile of the Company's SCS TM as a CSF catheter. |
Company's innovative SCSTM is designed to prevent obstruction in the cerebrospinal fluid (CSF) catheters implanted
in the ventricle of the brain of patients who suffer from hydrocephalus or Normal Pressure Hydrocephalus (NPH).
Microbot Medical, Inc.
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot's
current technological platforms, ViRobTM, TipCATTM and CardioSertTM, are comprised of three highly
advanced technologies, from which the Company is currently developing its first product candidate: the Self Cleaning Shunt, or
SCSTM, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and focusing on the development
of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot Medical is available
ViRobTM technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the
body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,
the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRobTM please visit
is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see & treat capabilities
within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCATTM,
technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSertTM technology features unique steering and stiffness control capabilities, and it was originally
developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during
percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as
peripheral intervention, neurosurgery and urology. CardioSertTM was part of a technological incubator supported by
the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully
completed pre-clinical testing.
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects" and "estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical
Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.'s filings with the Securities
and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.